NASDAQ:IMDZ - Immune Design Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.35 +0.17 (+4.07 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$4.35
Today's Range$4.05 - $4.40
52-Week Range$2.80 - $13.05
Volume194,170 shs
Average Volume425,984 shs
Market Capitalization$204.53 million
P/E Ratio-2.49
Dividend YieldN/A
Beta1.88

About Immune Design (NASDAQ:IMDZ)

Immune Design logoImmune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.

Receive IMDZ News and Ratings via Email

Sign-up to receive the latest news and ratings for IMDZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMDZ
CUSIPN/A
Phone206-682-0645

Debt

Debt-to-Equity RatioN/A
Current Ratio21.18
Quick Ratio21.08

Price-To-Earnings

Trailing P/E Ratio-2.49
Forward P/E Ratio-3.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.20 million
Price / Sales29.08
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book1.50

Profitability

EPS (Most Recent Fiscal Year)($1.75)
Net Income$-51,860,000.00
Net Margins-2,352.98%
Return on Equity-52.00%
Return on Assets-45.88%

Miscellaneous

Employees56
Outstanding Shares48,130,000

Immune Design (NASDAQ:IMDZ) Frequently Asked Questions

What is Immune Design's stock symbol?

Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."

How were Immune Design's earnings last quarter?

Immune Design (NASDAQ:IMDZ) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. The biotechnology company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.83 million. Immune Design had a negative return on equity of 52.00% and a negative net margin of 2,352.98%. View Immune Design's Earnings History.

When is Immune Design's next earnings date?

Immune Design is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Immune Design.

What price target have analysts set for IMDZ?

4 Wall Street analysts have issued 1 year target prices for Immune Design's stock. Their forecasts range from $8.00 to $20.00. On average, they expect Immune Design's share price to reach $12.6667 in the next twelve months. View Analyst Ratings for Immune Design.

Who are some of Immune Design's key competitors?

Who are Immune Design's key executives?

Immune Design's management team includes the folowing people:
  • Dr. Carlos V. Paya M.D., Ph.D., Chief Exec. Officer, Pres and Director (Age 59)
  • Mr. Stephen R. Brady J.D., LLM, Principal Financial Officer, Principal Accounting Officer and Exec. VP of Strategy & Fin. (Age 48)
  • Dr. Jan Henrik Ter Meulen M.D., DR. HABIL., DTM&H, Chief Scientific Officer (Age 55)
  • Mr. Christopher Whitmore CPA, VP of Fin. & Admin.
  • Dr. Wayne R. Gombotz Ph.D., Chief Devel. Officer (Age 59)

Has Immune Design been receiving favorable news coverage?

News headlines about IMDZ stock have trended positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immune Design earned a coverage optimism score of 0.28 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 44.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Immune Design's major shareholders?

Immune Design's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (8.53%), BlackRock Inc. (3.98%), JPMorgan Chase & Co. (1.75%), Dimensional Fund Advisors LP (0.40%) and DRW Securities LLC (0.08%). Company insiders that own Immune Design stock include Carlos V Paya, Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Meulen Jan Henrik Ter, Peter Svennilson, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design.

Which major investors are selling Immune Design stock?

IMDZ stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have sold Immune Design company stock in the last year include Carlos V Paya, Meulen Jan Henrik Ter, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Insider Buying and Selling for Immune Design.

Which major investors are buying Immune Design stock?

IMDZ stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Dimensional Fund Advisors LP, BlackRock Inc. and DRW Securities LLC. Company insiders that have bought Immune Design stock in the last two years include Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Peter Svennilson and Stephen R Brady. View Insider Buying and Selling for Immune Design.

How do I buy shares of Immune Design?

Shares of IMDZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Design's stock price today?

One share of IMDZ stock can currently be purchased for approximately $4.35.

How big of a company is Immune Design?

Immune Design has a market capitalization of $204.53 million and generates $7.20 million in revenue each year. The biotechnology company earns $-51,860,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 56 workers across the globe.

How can I contact Immune Design?

Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]


MarketBeat Community Rating for Immune Design (IMDZ)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe IMDZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immune Design (NASDAQ:IMDZ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Immune Design in the last 12 months. Their average twelve-month price target is $12.6667, suggesting that the stock has a possible upside of 191.19%. The high price target for IMDZ is $20.00 and the low price target for IMDZ is $8.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.6667$12.6667$16.00$16.00
Price Target Upside: 191.19% upside224.79% upside332.43% upside58.42% upside

Immune Design (NASDAQ:IMDZ) Consensus Price Target History

Price Target History for Immune Design (NASDAQ:IMDZ)

Immune Design (NASDAQ:IMDZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018Jefferies GroupReiterated RatingBuy$8.00HighView Rating Details
12/11/2017CowenReiterated RatingBuyLowView Rating Details
10/17/2017Wells FargoDowngradeOutperform ➝ Market Perform$29.00 ➝ $10.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$20.00LowView Rating Details
6/10/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Immune Design (NASDAQ:IMDZ) Earnings History and Estimates Chart

Earnings by Quarter for Immune Design (NASDAQ:IMDZ)

Immune Design (NASDAQ:IMDZ) Earnings Estimates

2018 EPS Consensus Estimate: ($1.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.31)($0.31)($0.31)
Q3 20182($0.39)($0.36)($0.38)
Q4 20182($0.40)($0.39)($0.40)

Immune Design (NASDAQ IMDZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018        
5/16/2018Q1($0.30)($0.28)ViewN/AView Earnings Details
5/2/2018Q1 2018($0.29)($0.28)$1.83 million$0.50 millionViewListenView Earnings Details
3/14/2018n/a($0.39)($0.29)$0.81 million$0.49 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.63)($0.52)$0.62 million$0.52 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.65)($0.54)$1.50 million$0.73 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.62)($0.50)$1.78 million$5.47 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.57)($0.57)$1.34 million$2.06 millionViewListenView Earnings Details
11/9/2016Q316($0.71)($0.60)$1.73 million$8.20 millionViewListenView Earnings Details
8/9/2016Q2($0.68)($0.71)$1.50 million$1.13 millionViewN/AView Earnings Details
5/10/2016Q1($0.62)($0.61)$0.85 million$1.86 millionViewListenView Earnings Details
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details
8/12/2015Q215($0.47)($0.54)$1.40 million$1.78 millionViewListenView Earnings Details
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details
3/31/2015Q4 2014($0.68)($0.78)$0.78 million$1.80 millionViewListenView Earnings Details
11/12/2014Q3 14($0.36)($0.55)$0.20 million$3.54 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Immune Design (NASDAQ:IMDZ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Immune Design (NASDAQ IMDZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.10%
Institutional Ownership Percentage: 50.70%
Insider Trading History for Immune Design (NASDAQ:IMDZ)
Institutional Ownership by Quarter for Immune Design (NASDAQ:IMDZ)

Immune Design (NASDAQ IMDZ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/8/2018Leo GuthartMajor ShareholderBuy20,000$3.90$78,000.00View SEC Filing  
1/5/2018Carlos V PayaCEOSell7,970$4.17$33,234.90114,560View SEC Filing  
1/5/2018Meulen Jan Henrik TerInsiderSell1,986$4.17$8,281.6241,020View SEC Filing  
1/5/2018Stephen R BradyEVPSell3,328$4.17$13,877.7650,490View SEC Filing  
1/4/2018Sergey YurasovVPSell675$4.17$2,814.7528,000View SEC Filing  
11/2/2017Lewis W ColemanDirectorBuy50,000$4.50$225,000.00View SEC Filing  
10/30/2017Franklin M BergerDirectorBuy25,000$4.58$114,500.0075,000View SEC Filing  
10/27/2017Leo GuthartMajor ShareholderBuy2,439,000$4.10$9,999,900.00View SEC Filing  
10/27/2017Peter SvennilsonDirectorBuy2,681,000$4.10$10,992,100.00View SEC Filing  
10/25/2017Franklin M BergerDirectorBuy25,000$4.26$106,500.0050,000View SEC Filing  
10/24/2017Leo GuthartMajor ShareholderBuy60,000$4.65$279,000.00View SEC Filing  
10/19/2017Leo GuthartMajor ShareholderBuy10,000$6.09$60,900.00View SEC Filing  
9/18/2017Leo GuthartMajor ShareholderBuy10,000$9.70$97,000.00View SEC Filing  
8/1/2017Wayne GombotzInsiderSell10,000$11.43$114,300.0033,054View SEC Filing  
7/11/2017Lewis W ColemanDirectorBuy12,000$9.05$108,600.0040,000View SEC Filing  
7/10/2017Lewis W ColemanDirectorBuy10,000$9.00$90,000.0040,000View SEC Filing  
7/7/2017Lewis W ColemanDirectorBuy8,000$9.27$74,160.0040,000View SEC Filing  
1/4/2017Carlos V PayaInsiderSell3,940$5.35$21,079.0072,000View SEC Filing  
1/4/2017Stephen R BradyEVPSell1,642$5.35$8,784.7032,132View SEC Filing  
12/22/2016Lewis W ColemanDirectorSell10,000$6.20$62,000.0040,000View SEC Filing  
12/16/2016Franklin M BergerDirectorSell50,000$6.55$327,500.0025,000View SEC Filing  
9/20/2016Group L P ColumnMajor ShareholderBuy800,000$6.25$5,000,000.00View SEC Filing  
9/20/2016Lewis W ColemanDirectorBuy40,000$6.25$250,000.0050,000View SEC Filing  
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.0017,132View SEC Filing  
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.0034View SEC Filing  
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.0034View SEC Filing  
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.0010,000View SEC Filing  
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Immune Design (NASDAQ IMDZ) News Headlines

Source:
DateHeadline
Immune Design (IMDZ) Given Average Recommendation of "Buy" by AnalystsImmune Design (IMDZ) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 1:34 AM
Immune Design (IMDZ) Upgraded by ValuEngine to "Sell"Immune Design (IMDZ) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 17 at 4:41 PM
Immune Design (IMDZ) Issues Quarterly  Earnings ResultsImmune Design (IMDZ) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 10:35 AM
Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking TherapeuticsLucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
seekingalpha.com - May 16 at 8:14 AM
Immune Design Nearing Critical Point In ValuationImmune Design Nearing Critical Point In Valuation
seekingalpha.com - May 11 at 6:04 PM
Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry StocksComplimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks
finance.yahoo.com - May 11 at 8:16 AM
Immune Design (IMDZ) to Release Quarterly Earnings on TuesdayImmune Design (IMDZ) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 8 at 2:26 AM
Q3 2018 EPS Estimates for Immune Design Lifted by Leerink Swann (IMDZ)Q3 2018 EPS Estimates for Immune Design Lifted by Leerink Swann (IMDZ)
www.americanbankingnews.com - May 7 at 3:12 AM
Jefferies Group Equities Analysts Raise Earnings Estimates for Immune Design (IMDZ)Jefferies Group Equities Analysts Raise Earnings Estimates for Immune Design (IMDZ)
www.americanbankingnews.com - May 7 at 2:07 AM
Immune Designs (IMDZ) CEO Dr. Carlos Paya on Q1 2018 Results - Earnings Call TranscriptImmune Design's (IMDZ) CEO Dr. Carlos Paya on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 8:10 AM
Immune Design: 1Q Earnings SnapshotImmune Design: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:10 AM
Edited Transcript of IMDZ earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of IMDZ earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 8:10 AM
Immune Design (IMDZ) Posts  Earnings Results, Beats Expectations By $0.01 EPSImmune Design (IMDZ) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 10:02 PM
Immune Design beats by $0.01, misses on revenueImmune Design beats by $0.01, misses on revenue
seekingalpha.com - May 2 at 5:40 PM
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate UpdateImmune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 2 at 5:40 PM
Immune Design Corp (IMDZ) Given Consensus Rating of "Buy" by BrokeragesImmune Design Corp (IMDZ) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 27 at 1:29 AM
Whats in the Cards for Immune Design (IMDZ) in Q1 Earnings?What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
www.msn.com - April 26 at 5:20 PM
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
finance.yahoo.com - April 26 at 5:20 PM
Immune Design (IMDZ) to Release Quarterly Earnings on WednesdayImmune Design (IMDZ) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 26 at 8:28 AM
Tetraphase Pharmaceuticals (TTPH) & Immune Design (IMDZ) Head-To-Head ContrastTetraphase Pharmaceuticals (TTPH) & Immune Design (IMDZ) Head-To-Head Contrast
www.americanbankingnews.com - April 25 at 11:14 PM
Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate UpdateImmune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
finance.yahoo.com - April 25 at 8:13 AM
Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report?Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report?
finance.yahoo.com - April 13 at 5:37 PM
Immune Design (IMDZ) Raised to Hold at ValuEngineImmune Design (IMDZ) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
ValuEngine Lowers Immune Design (IMDZ) to SellValuEngine Lowers Immune Design (IMDZ) to Sell
www.americanbankingnews.com - April 8 at 11:49 AM
Immune Design Corp (IMDZ) Receives Consensus Recommendation of "Buy" from BrokeragesImmune Design Corp (IMDZ) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 2 at 1:30 AM
Immune Design (IMDZ) Cut to "Hold" at Zacks Investment ResearchImmune Design (IMDZ) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 12:34 PM
Immune Design Corp (NASDAQ:IMDZ): Earnings To Drop Next Year, Is It A Long-Term Trend?Immune Design Corp (NASDAQ:IMDZ): Earnings To Drop Next Year, Is It A Long-Term Trend?
finance.yahoo.com - March 22 at 8:20 AM
Jefferies Group Weighs in on Immune Design Corps Q1 2018 Earnings (IMDZ)Jefferies Group Weighs in on Immune Design Corp's Q1 2018 Earnings (IMDZ)
www.americanbankingnews.com - March 19 at 1:40 AM
Immune Design reports 4Q loss - Yahoo FinanceImmune Design reports 4Q loss - Yahoo Finance
finance.yahoo.com - March 17 at 8:20 AM
Immune Design Corp to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (IMDZ)Immune Design Corp to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (IMDZ)
www.americanbankingnews.com - March 16 at 4:20 PM
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4 - NasdaqImmune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 16 at 8:13 AM
Immune Designs (IMDZ) "Buy" Rating Reaffirmed at Jefferies GroupImmune Design's (IMDZ) "Buy" Rating Reaffirmed at Jefferies Group
www.americanbankingnews.com - March 15 at 5:46 PM
Immune Design Corp. to Host Earnings CallImmune Design Corp. to Host Earnings Call
www.baystreet.ca - March 14 at 7:12 PM
Interested In Immune Design Corp (NASDAQ:IMDZ)? Here’s How It Performed RecentlyInterested In Immune Design Corp (NASDAQ:IMDZ)? Here’s How It Performed Recently
finance.yahoo.com - March 14 at 7:12 PM
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateImmune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 7:12 PM
$810,000.00 in Sales Expected for Immune Design Corp (IMDZ) This Quarter$810,000.00 in Sales Expected for Immune Design Corp (IMDZ) This Quarter
www.americanbankingnews.com - March 14 at 5:02 AM
Immune Design (IMDZ) Upgraded by Zacks Investment Research to "Buy"Immune Design (IMDZ) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 13 at 7:28 PM
Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine DevelopmentIntegral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development
www.bizjournals.com - March 13 at 7:22 PM
When Corporate Social Responsibility Veers Into Political Action: Safe Or Sorry?When Corporate Social Responsibility Veers Into Political Action: Safe Or Sorry?
www.forbes.com - March 13 at 7:22 PM
Immune Design (IMDZ) Announces Data Update for Lead Immunotherapy ProgramsImmune Design (IMDZ) Announces Data Update for Lead Immunotherapy Programs
www.streetinsider.com - March 12 at 6:44 PM
Immune Design (IMDZ) Downgraded by Zacks Investment Research to "Hold"Immune Design (IMDZ) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 12 at 3:14 PM
Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular LymphomaImmune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
finance.yahoo.com - March 12 at 8:35 AM
Immune Design (IMDZ) to Release Earnings on WednesdayImmune Design (IMDZ) to Release Earnings on Wednesday
www.americanbankingnews.com - March 8 at 9:47 AM
Immune Design Corp (IMDZ) Given Average Rating of "Hold" by BrokeragesImmune Design Corp (IMDZ) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 8 at 1:24 AM
Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate UpdateImmune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - March 7 at 8:12 AM
Analyzing Immune Design (IMDZ) & Achaogen (AKAO)Analyzing Immune Design (IMDZ) & Achaogen (AKAO)
www.americanbankingnews.com - March 5 at 11:36 AM
Whats Happening With These Biotech Stocks? -- Illumina, Immune Design, ImmunoCellular Therapeutics, and ... - PR Newswire (press release)What's Happening With These Biotech Stocks? -- Illumina, Immune Design, ImmunoCellular Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - February 28 at 8:13 AM
Whats in the Cards for Immune Design (IMDZ) in Q4 Earnings?What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
www.nasdaq.com - February 27 at 5:58 PM
What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
finance.yahoo.com - February 27 at 8:14 AM
 Analysts Expect Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00 Analysts Expect Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - February 25 at 3:48 AM

SEC Filings

Immune Design (NASDAQ:IMDZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Immune Design (NASDAQ:IMDZ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Immune Design (NASDAQ IMDZ) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.